Better Health for All
0
Altimmune is a clinical-stage biopharmaceutical company entirely focused on developing novel therapies for serious liver diseases, Alcohol Use Disorder (AUD), and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its lead candidate, Pemvidutide, targets conditions that can lead to severe health outcomes like cirrhosis, liver failure, and cancer, and has received FDA Breakthrough Therapy Designation for MASH
1
and Fast Track Designation for MASH and AUD
2
. As a result, 100% of the company's R&D and capital allocation is dedicated to health improvement, including the use of a novel peptide and an FDA-qualified AI pathology tool in clinical trials
3
. The company has no revenue from products with negative health impacts. Clinical trials for Pemvidutide have shown a favorable tolerability profile and lower discontinuation rates due to adverse events compared to placebo at 48 weeks
4
. The company conducts publicly registered clinical trials (e.g., NCT06987513)
5
with randomized, placebo-controlled designs and clear endpoints. Its Code of Business Conduct and Ethics mandates compliance with all applicable laws
6
, and the company states its aim to provide "full, fair, accurate, timely and understandable disclosure" in SEC filings and public communications, including forward-looking statements with risk cautions
7
. The company's development of therapies for AUD and Alcohol-associated Liver Disease (ALD) directly addresses the significant negative health externalities of harmful alcohol consumption and supports recovery from addiction
8
. However, the company's primary focus is on treatment rather than broader disease prevention or health promotion initiatives. While AUD is a mental health condition
9
, no broader mental health initiatives are mentioned beyond drug development. As products are in clinical trials, there is no information available regarding pricing, accessibility, or specific reach to vulnerable populations. The company's Code of Conduct mandates confidentiality of information
10
, but specific details on health data privacy safeguards are not provided.
Fair Money & Economic Opportunity
0
Altimmune, Inc. is a clinical-stage biopharmaceutical company, not a financial institution. As such, its core business does not involve lending, insuring, moving, or storing money for consumers. Consequently, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable. The company does not offer consumer credit products, financial services, or operate financial service access points. While it has a 'culture of inclusion'
1
and its Board considers diverse backgrounds
2
, these relate to internal governance and employee management, not financial inclusion initiatives for underserved customer segments. The company provides employees with opportunities to participate in equity programs
3
, but this does not directly impact customer credit or savings outcomes. It intends to retain future earnings for growth
4
, which is a standard business practice, not community finance reinvestment. The company makes SEC filings available on its website
5
, but this is not related to customer financial data portability.
Fair Pay & Worker Respect
0
Altimmune's CEO, Vipin Garg, received total compensation of US$1.4 million in 2020
1
, a 76% increase from 2019
2
, which was lower than the industry median of US$3.0 million for comparable companies
3
. His salary constituted 36% of his 2020 remuneration
4
, exceeding the industry average of 20%
5
. In fiscal year 2024, his total compensation was $6,090,462.
6
The incoming CEO, effective January 1, 2026, has an annual base salary of $725,000.
7
The company's Code of Business Conduct and Ethics, effective January 27, 2026, affirms employees' rights under the National Labor Relations Act, including discussing employment issues and sharing compensation information.
8
The Code also establishes an ethics hotline and online reporting, prohibiting retaliation for good-faith misconduct reports.
9
No regulatory actions, violations, fines, or compliance issues were mentioned in 2020 or fiscal year 2024.
10
,
11
The company received an overall Glassdoor rating of 4.0 in September 2024
12
, but employee satisfaction with compensation and benefits was rated -1/5 stars in a July 2025 review.
13
Fair Trade & Ethical Sourcing
0
The provided articles, which include proxy statements, SEC filings (Form 10-K), and the company's Code of Business Conduct and Ethics, do not contain specific information or quantitative data relevant to the Fair Trade & Ethical Sourcing KPIs.
1
There is no evidence regarding fair-trade certification share, supplier audit frequency, forced or child labor incidents, supply chain traceability coverage, remediation speed for violations, ethical clauses in supplier contracts, share of spend on high-risk materials, or supplier diversity spend.
2
While a Code of Business Conduct and Ethics is mentioned, it does not specify the inclusion or enforcement of ethical sourcing clauses within supplier contracts, nor does it provide any quantitative data on supplier-related ethical practices.
3
Honest & Fair Business
10
Altimmune, Inc. has not reported any ethics-related regulatory fines in the past three years.
1
Its independent auditor, Ernst & Young LLP, issued clean reports on the company's financial statements for 2023 and 2024, with no adverse opinions, disclaimers, or disagreements, implying no financial restatements for those years
2
and approximately 100% audit coverage of financial statements. The board of directors demonstrates strong independence, with 6 out of 7 directors meeting Nasdaq independence requirements (~85.7%).
3
The company has a Code of Business Conduct and Ethics,
4
and policies and procedures to ensure compliance with anti-corruption laws and the Foreign Corrupt Practices Act.
5
A comprehensive whistleblower policy is in place, explicitly protecting employees' rights to communicate with government agencies and receive awards,
6
and providing an ethics hotline and online reporting channels.
7
However, the company is currently facing a significant ESG controversy. A class action complaint was filed in August 2025,
8
and a law firm is investigating potential breaches of fiduciary duties by the board.
9
This followed a 53.2% stock price decline in June 2025 after a Phase 2b clinical trial failed to meet its primary endpoint.
10
No information is available regarding a recognized transparency index or median complaint resolution times.
Kind to Animals
-10
Altimmune, Inc. extensively uses animal testing for product development. SparVax™ is developed under the Animal Rule, allowing efficacy testing in animal models instead of clinical trials.
1
Preclinical studies for Valortim®, Protexia®, and RypVax™ are conducted in animal models, including non-human primates and rabbits, with some involving lethal aerosol challenges.
2
The company's animal testing policy mandates compliance with existing regulations such as the FDA's Good Laboratory Practices, the U.S. Department of Agriculture’s Animal Welfare Act, and the Public Health Service Policy on Humane Care and Use of Laboratory Animals.
3
There is no evidence of the company employing non-animal testing methods or having a policy to reduce or replace animal testing. Additionally, Altimmune owns and operates a 180-acre farm in Canada where transgenic goats are raised to produce a starting material for Protexia®.
4
No War, No Weapons
0
Altimmune's technology for developing medicines and vaccines is considered dual-use, with the potential for application in biological weapons.
1
The company's research and development of synthetic poxviruses is dedicated to public health while also safeguarding information with broad, dual-use potential that could be inappropriately applied.
2
An example of this is their NasoShield vaccine candidate for anthrax.
3
Additionally, Altimmune received a $4.7 million award from the U.S. Army Medical Research & Development Command (USAMRDC) to fund a Phase 1/2 clinical trial of T-COVID.
4
Planet-Friendly Business
0
The provided articles do not contain specific environmental performance data for Altimmune, Inc.
1
Several articles explicitly state a lack of information regarding sustainability metrics.
2
While the company's research and development involve hazardous materials
3
and it is subject to various environmental regulations
4
, no data on actual emissions, renewable energy use, waste diversion, water usage, environmental compliance violations, or other specific planet-friendly business metrics is available.
5
Respect for Cultures & Communities
0
The provided articles do not contain specific information regarding Altimmune, Inc.'s practices related to 'Respect for Cultures & Communities'. There is no evidence available concerning formal partnerships with indigenous or local community groups, cultural appropriation incidents, or the existence of a cultural impact assessment protocol. Similarly, information on the proportion of affected communities participating in FPIC processes, community representation in governance bodies, or specific investments in cultural preservation programs is absent. Details on the number of indigenous suppliers engaged, actions taken to protect cultural sites, the percentage of operations with a social license, or the distribution of non-core revenue to community development funds are also not provided. The articles also lack information on local employment ratios, grievance mechanisms, complaint resolution times, local procurement, charitable giving to cultural organizations, language inclusivity, cultural incident response frameworks, or cultural sensitivity training completion rates.
Safe & Smart Tech
10
Altimmune, Inc. has no documented data breaches. The company's AI models, specifically AIM-MASH, are developed using Good Clinical Practice/Good Clinical Laboratory Practice principles and in accordance with the Declaration of Helsinki.
1
Anonymized liver tissue samples are used, and pathologists for model development are required to pass proficiency examinations.
2
To correct for pathologist bias, GNN models are specified as 'mixed effects' models, with bias parameters learned during training and discarded at test time.
3
AIM-MASH performance is rigorously tested, including 100% repeatability for algorithm scoring, assessment using a mixed leave-one-out approach, and ongoing validation studies across 605 WSIs.
4
The AI model architecture, training data, and processes are described, with predictions displayed as colorized overlays for pathologist review.
5
All employees and contractors receive cybersecurity training.
6
The company identifies assets at risk, implements protective measures including patching and Multi-Factor Authentication (MFA), and conducts quarterly third-party security assessments.
7
For the AIM-MASH study, anonymized data was used, and informed consent was obtained, with data maintained to preserve patient confidentiality.
8
The company is committed to complying with all applicable laws, including the Foreign Corrupt Practices Act, international trade regulations, and SEC disclosure requirements.
9
AIM-MASH is also being evaluated by the FDA and EMA for qualification as a drug discovery tool.
10
Users who register on the website can see, edit, delete, request export, or erase their personal information, though usernames cannot be changed.
11
The website tracks IP addresses and browser information for traffic analysis.
12
Login cookies last for two days, and "Remember Me" functionality persists for two weeks.
13
The company does not provide specific figures for cybersecurity investment, privacy certifications, encryption implementation details, or bug bounty programs.
14
There are no documented incidents of unauthorized data use, and the company maintains a neutral stance on digital rights advocacy.
Zero Waste & Sustainable Products
-10
Altimmune, Inc. is developing a dry powder version of a vaccine, a design choice intended to eliminate the risk of hazardous waste from needles
1
. This reflects a focus on hazardous waste minimization and circular design considerations for some product lines. The company's financial report for the period ending June 30, 2018, does not mention any waste disposal violations
2
. No zero waste or sustainability certifications are mentioned in the available documents
3
.